Chief executive officer Mark Alles has been appointed to the additional role of chairman of the board of directors.
Bob Hugin joined Celgene in 1999 as chief financial officer. He served as president and chief operating officer from 2006 to 2010, and chief executive officer from 2010 until becoming Executive chairman in March 2016. Hugin was elected to serve on the board of directors in December 2001 and became chairman in June 2011.
CEO and newly appointed chairman Mark Alles has been with Celgene since 2004. Prior to becoming CEO in 2016, Mark served as president and COO, and prior to that, as executive vice president and global head of hematology and oncology, helping to build the company's hematology and oncology franchise, as well as various other senior leadership positions.
Celgene is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007